Daidzin

CAS No. 552-66-9

Daidzin ( Daidzoside; NPI 031D )

Catalog No. M15003 CAS No. 552-66-9

Daidzin is an isoflavone that has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 59 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Daidzin
  • Note
    Research use only, not for human use.
  • Brief Description
    Daidzin is an isoflavone that has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.
  • Description
    Daidzin is an isoflavone that has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities; directly inhibits mitochondrial aldehyde dehydrogenase 2 (IC50 = 80 nM) and is an effective anti-dipsotropic isoflavone.
  • Synonyms
    Daidzoside; NPI 031D
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    ALDH-Ⅰ; ALDH-Ⅱ
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    552-66-9
  • Formula Weight
    416.37
  • Molecular Formula
    C21H20O9
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C1C(C2=CC=C(O)C=C2)=COC3=C1C=CC(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)=C3
  • Chemical Name
    3-(4-Hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zaheer M, Reddy VD, Giri CC. Nat Prod Res. 2015 Jul 8:1-6.
molnova catalog
related products
  • hDHODH-IN-5

    hDHODH-IN-5 is an inhibitor of human dihydroorotate dehydrogenase.

  • Atovaquone

    Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.

  • Dovitinib Dilactic A...

    Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor.